Depression Screening and Mental Health Market US$ 11245.6 Million by 2023

“Market Research Futurern”
World Depression Screening and Mental Health Market report provides market overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market.

The World Depression Screening and Mental Health Market report explores Some of the key players in this market are: Alkermes (Republic of Ireland), ALLERGAN (Republic of Ireland), AstraZeneca (UK), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Johnson & Johnson Services, Inc. (US), Novartis AG (Switzerland), Otsuka Holdings Co.,Ltd. (Japan), Pfizer Inc. (US), and others.

Get Sample PDF Illustration @ .

Sources: World Health Organization (WHO), U.S. Department of Health & Human Services, International Journal of Behavioral Science, Canadian Mental Health Association, Directorate of Industries, Annual report, White paper, Company Presentation.

Global Depression Screening and Mental Health Market Synopsis:

Depression and mental health are the major health issues across the globe. Increasing prevalence of various mental disorder, social and environmental changes, and changing lifestyle are major drivers for the market growth. Rising funding for R&D and clinical trials are also driving the growth for the market. Increasing awareness of disorders and treatments, rapid adoption of new therapies and treatments, and technological advancement are key drivers for the market.

The Depression Screening and Mental Health Market information, by disorder (anxiety, mood disorders, depression, bipolar, psychotic, and others), by diagnosis (psychological test, lab tests, depression screening tests, and others) by treatment (medication, psychotherapy, and others), by end user- Global Forecast till 2023

The global depression screening/mental health market is growing at the CAGR of ~4.5% during the forecast period and expected to reach US$ 11245.6 million by 2023.

Global depression screening/mental health market has been segmented on the basis of disorder which comprises of anxiety, mood disorders, depression, bipolar behavior, psychosis, eating disorders, impulse control & addiction disorders, personality disorders, stress response syndromes, dissociative disorder, somatic symptom disorder, factitious disorder, and others. Anxiety is further sub-segmented into Generalized Anxiety Disorder (GAD), panic disorder, phobias, Obsessive-Compulsive Disorder (OCD), Post-Traumatic Stress Disorder (PTSD). Mood disorder is further sub-segmented into dysthymia, substance-induced mood disorder, major depression, and others. Depression is further sub-segmented into atypical depression, chronic depression, melancholic depression, catatonic depression, Seasonal affective disorder (SAD), and others.

Get Discount @ .

On the basis of diagnosis, the market has been segmented into psychological test, Lab tests, Depression Screening Tests and others. Psychological test is further sub-segmented into intelligence tests, attitude tests, personality tests, achievement tests, and others. Lab tests sub-segmented into blood tests, CT scan or MRI of the brain, Electroencephalogram (EEG), Electrocardiogram (ECG). Depression Screening Tests includes Patient Health Questionnaire-10 (PHQ-10), Beck Depression Inventory (BDI), Zung Self-Rating Depression Scale, Center for Epidemiologic Studies-Depression Scale (CES-D), and Hamilton Rating Scale for Depression (HRSD).

On the basis of treatment, the market has been segmented into medication, psychotherapy, brain-stimulation treatments, hospitalization, substance abuse treatment, and others. Medication includes anti-anxiety medications, antidepressants, antipsychotic medications, mood-stabilizing medications, opioid antagonists, atypical neuroleptics, glutamatergic agents, and others. Psychotherapy is further sub-segmented into cognitive and behavioural therapies, humanistic therapies, psychoanalytical and psychodynamic therapies, and others. Brain-stimulation treatments includes repetitive Transcranial Magnetic Stimulation (rTMS), Vagus Nerve Stimulation (VNS), Deep Brain Stimulation (DBS), Vagus Nerve Stimulation (VNS), and others.

Inquire more @ .

Regional analysis of global depression screening/mental health market:

Considering the global scenario of the market, the Americas hold the largest market share due to various factors such as availability advanced diagnostic and treatment, funding for research, increasing number of patients with mental illness and related disorders. Increasing stress and changing lifestyle is driving the growth for European Depression Screening/Mental Health market. It is the second largest where the west European countries are dominating the largest market share. Increasing prevalence of mental disorders, rapidly changing healthcare sector, and increasing healthcare spending are major growth drivers for Asia Pacific Depression Screening/Mental Health market. Middle East & Africa (ME&A) is likely to have a limited growth in the market due to some major factors like low knowledge of disorders and treatments, low-income, and limited access to healthcare facilities.


Media Contact
Company Name: Market Research Future
Contact Person: Akash Anand
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune –
City: Pune
State: Maharashtra
Country: India